Publicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (16)

2024

  1. How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 6

  2. Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

    Blood Advances

  3. The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model

    Pediatric Drugs, Vol. 26, Núm. 3, pp. 331-346

2023

  1. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  2. Measuring DNA modifications with the comet assay: a compendium of protocols

    Nature Protocols, Vol. 18, Núm. 3, pp. 929-989

2022

  1. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  2. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy

    Clinical Microbiology and Infection, Vol. 28, Núm. 9, pp. 1287.e9-1287.e15

2021

  1. Author Correction: DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death (Scientific Reports, (2021), 11, 1, (16793), 10.1038/s41598-021-95976-7)

    Scientific Reports

  2. DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death

    Scientific Reports, Vol. 11, Núm. 1

  3. The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders

    Mutation Research - Reviews in Mutation Research, Vol. 787

2020

  1. Finding the dose for ceftolozane-tazobactam in critically ill children with and without acute kidney injury

    Antibiotics, Vol. 9, Núm. 12, pp. 1-14

2019

  1. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

    Leukemia Research, Vol. 76, pp. 1-10

2016

  1. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Critical Care, Vol. 20, Núm. 1

2014

  1. Base excision repair capacity in chronic renal failure patients undergoing hemodialysis treatment

    Cell Biochemistry and Function, Vol. 32, Núm. 2, pp. 177-182

2012

  1. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

2006

  1. Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor

    Pharmaceutical Research, Vol. 23, Núm. 7, pp. 1533-1542